Cargando…

Oxytocin Protects Against Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting PI3K/AKT Pathway via a lncRNA GAS5/miR-375-3p/KLF4-Dependent Mechanism

Cardiac hypertrophy is caused by cardiac volume or pressure overload conditions and ultimately leads to contractile dysfunction and heart failure. Oxytocin (OT), an endocrine nonapeptide, has been identified as a cardiovascular homeostatic hormone with anti-hypertrophic effects. However, the underly...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yuqiao, Wang, Zhuoran, Yao, Mengran, Xiong, Wei, Wang, Jun, Fang, Yu, Yang, Wei, Jiang, Haixia, Song, Ning, Liu, Lan, Qian, Jinqiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678504/
https://www.ncbi.nlm.nih.gov/pubmed/34925023
http://dx.doi.org/10.3389/fphar.2021.766024
_version_ 1784616320169410560
author Yang, Yuqiao
Wang, Zhuoran
Yao, Mengran
Xiong, Wei
Wang, Jun
Fang, Yu
Yang, Wei
Jiang, Haixia
Song, Ning
Liu, Lan
Qian, Jinqiao
author_facet Yang, Yuqiao
Wang, Zhuoran
Yao, Mengran
Xiong, Wei
Wang, Jun
Fang, Yu
Yang, Wei
Jiang, Haixia
Song, Ning
Liu, Lan
Qian, Jinqiao
author_sort Yang, Yuqiao
collection PubMed
description Cardiac hypertrophy is caused by cardiac volume or pressure overload conditions and ultimately leads to contractile dysfunction and heart failure. Oxytocin (OT), an endocrine nonapeptide, has been identified as a cardiovascular homeostatic hormone with anti-hypertrophic effects. However, the underlying mechanism remains elusive. In this study, we aimed to investigate the role and mechanism of OT in cardiac hypertrophy. The rats with cardiac hypertrophy induced by isoproterenol (ISO) were treated with or without oxytocin. Cardiac functional parameters were analyzed by echocardiography. The changes in cell surface area were observed using wheat germ agglutinin (WGA) or immunofluorescence staining. The expressions of cardiac hypertrophy markers (B-Natriuretic Peptide, BNP and β-myosin heavy chain, β-MHC), long non-coding RNA Growth (LcRNA) Arrest-Specific transcript 5 (lncRNA GAS5), miR-375-3p, and Kruppel-like factor 4 (Klf4) were detected by qRT-PCR. KLF4 protein and PI3K/AKT pathway related proteins were detected by Western blot. The interactions among lncRNA GAS5, miR-375-3p, and Klf4 were verified by dual-luciferase reporter assays. The findings showed that OT significantly attenuated cardiac hypertrophy, increased expressions of lncRNA GAS5 and KLF4, and decreased miR-375-3p expression. In vitro studies demonstrated that either knock-down of lncRNA GAS5 or Klf4, or over-expression of miR-375-3p blunted the anti-hypertrophic effects of OT. Moreover, down-regulation of lncRNA GAS5 promoted the expression of miR-375-3p and inhibited KLF4 expression. Similarly, over-expression of miR-375-3p decreased the expression of KLF4. Dual-luciferase reporter assays validated that lncRNA GAS5 could sponge miR-375-3p and Klf4 was a direct target gene of miR-375-3p. In addition, OT could inactivate PI3K/AKT pathway. The functional rescue experiments further identified OT regulated PI3K/AKT pathway through lncRNA GAS5/miR-375-3p/KLF4 axis. In summary, our study demonstrates that OT ameliorates cardiac hypertrophy by inhibiting PI3K/AKT pathway via lncRNA GAS5/miR-375-3p/KLF4 axis.
format Online
Article
Text
id pubmed-8678504
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86785042021-12-18 Oxytocin Protects Against Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting PI3K/AKT Pathway via a lncRNA GAS5/miR-375-3p/KLF4-Dependent Mechanism Yang, Yuqiao Wang, Zhuoran Yao, Mengran Xiong, Wei Wang, Jun Fang, Yu Yang, Wei Jiang, Haixia Song, Ning Liu, Lan Qian, Jinqiao Front Pharmacol Pharmacology Cardiac hypertrophy is caused by cardiac volume or pressure overload conditions and ultimately leads to contractile dysfunction and heart failure. Oxytocin (OT), an endocrine nonapeptide, has been identified as a cardiovascular homeostatic hormone with anti-hypertrophic effects. However, the underlying mechanism remains elusive. In this study, we aimed to investigate the role and mechanism of OT in cardiac hypertrophy. The rats with cardiac hypertrophy induced by isoproterenol (ISO) were treated with or without oxytocin. Cardiac functional parameters were analyzed by echocardiography. The changes in cell surface area were observed using wheat germ agglutinin (WGA) or immunofluorescence staining. The expressions of cardiac hypertrophy markers (B-Natriuretic Peptide, BNP and β-myosin heavy chain, β-MHC), long non-coding RNA Growth (LcRNA) Arrest-Specific transcript 5 (lncRNA GAS5), miR-375-3p, and Kruppel-like factor 4 (Klf4) were detected by qRT-PCR. KLF4 protein and PI3K/AKT pathway related proteins were detected by Western blot. The interactions among lncRNA GAS5, miR-375-3p, and Klf4 were verified by dual-luciferase reporter assays. The findings showed that OT significantly attenuated cardiac hypertrophy, increased expressions of lncRNA GAS5 and KLF4, and decreased miR-375-3p expression. In vitro studies demonstrated that either knock-down of lncRNA GAS5 or Klf4, or over-expression of miR-375-3p blunted the anti-hypertrophic effects of OT. Moreover, down-regulation of lncRNA GAS5 promoted the expression of miR-375-3p and inhibited KLF4 expression. Similarly, over-expression of miR-375-3p decreased the expression of KLF4. Dual-luciferase reporter assays validated that lncRNA GAS5 could sponge miR-375-3p and Klf4 was a direct target gene of miR-375-3p. In addition, OT could inactivate PI3K/AKT pathway. The functional rescue experiments further identified OT regulated PI3K/AKT pathway through lncRNA GAS5/miR-375-3p/KLF4 axis. In summary, our study demonstrates that OT ameliorates cardiac hypertrophy by inhibiting PI3K/AKT pathway via lncRNA GAS5/miR-375-3p/KLF4 axis. Frontiers Media S.A. 2021-12-03 /pmc/articles/PMC8678504/ /pubmed/34925023 http://dx.doi.org/10.3389/fphar.2021.766024 Text en Copyright © 2021 Yang, Wang, Yao, Xiong, Wang, Fang, Yang, Jiang, Song, Liu and Qian. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yang, Yuqiao
Wang, Zhuoran
Yao, Mengran
Xiong, Wei
Wang, Jun
Fang, Yu
Yang, Wei
Jiang, Haixia
Song, Ning
Liu, Lan
Qian, Jinqiao
Oxytocin Protects Against Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting PI3K/AKT Pathway via a lncRNA GAS5/miR-375-3p/KLF4-Dependent Mechanism
title Oxytocin Protects Against Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting PI3K/AKT Pathway via a lncRNA GAS5/miR-375-3p/KLF4-Dependent Mechanism
title_full Oxytocin Protects Against Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting PI3K/AKT Pathway via a lncRNA GAS5/miR-375-3p/KLF4-Dependent Mechanism
title_fullStr Oxytocin Protects Against Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting PI3K/AKT Pathway via a lncRNA GAS5/miR-375-3p/KLF4-Dependent Mechanism
title_full_unstemmed Oxytocin Protects Against Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting PI3K/AKT Pathway via a lncRNA GAS5/miR-375-3p/KLF4-Dependent Mechanism
title_short Oxytocin Protects Against Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting PI3K/AKT Pathway via a lncRNA GAS5/miR-375-3p/KLF4-Dependent Mechanism
title_sort oxytocin protects against isoproterenol-induced cardiac hypertrophy by inhibiting pi3k/akt pathway via a lncrna gas5/mir-375-3p/klf4-dependent mechanism
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678504/
https://www.ncbi.nlm.nih.gov/pubmed/34925023
http://dx.doi.org/10.3389/fphar.2021.766024
work_keys_str_mv AT yangyuqiao oxytocinprotectsagainstisoproterenolinducedcardiachypertrophybyinhibitingpi3kaktpathwayviaalncrnagas5mir3753pklf4dependentmechanism
AT wangzhuoran oxytocinprotectsagainstisoproterenolinducedcardiachypertrophybyinhibitingpi3kaktpathwayviaalncrnagas5mir3753pklf4dependentmechanism
AT yaomengran oxytocinprotectsagainstisoproterenolinducedcardiachypertrophybyinhibitingpi3kaktpathwayviaalncrnagas5mir3753pklf4dependentmechanism
AT xiongwei oxytocinprotectsagainstisoproterenolinducedcardiachypertrophybyinhibitingpi3kaktpathwayviaalncrnagas5mir3753pklf4dependentmechanism
AT wangjun oxytocinprotectsagainstisoproterenolinducedcardiachypertrophybyinhibitingpi3kaktpathwayviaalncrnagas5mir3753pklf4dependentmechanism
AT fangyu oxytocinprotectsagainstisoproterenolinducedcardiachypertrophybyinhibitingpi3kaktpathwayviaalncrnagas5mir3753pklf4dependentmechanism
AT yangwei oxytocinprotectsagainstisoproterenolinducedcardiachypertrophybyinhibitingpi3kaktpathwayviaalncrnagas5mir3753pklf4dependentmechanism
AT jianghaixia oxytocinprotectsagainstisoproterenolinducedcardiachypertrophybyinhibitingpi3kaktpathwayviaalncrnagas5mir3753pklf4dependentmechanism
AT songning oxytocinprotectsagainstisoproterenolinducedcardiachypertrophybyinhibitingpi3kaktpathwayviaalncrnagas5mir3753pklf4dependentmechanism
AT liulan oxytocinprotectsagainstisoproterenolinducedcardiachypertrophybyinhibitingpi3kaktpathwayviaalncrnagas5mir3753pklf4dependentmechanism
AT qianjinqiao oxytocinprotectsagainstisoproterenolinducedcardiachypertrophybyinhibitingpi3kaktpathwayviaalncrnagas5mir3753pklf4dependentmechanism